HMGB1 and neoplasm: Moreover, it has been shown that HMGB1-deficient tumors resist DNA-alkylating therapies and have an impaired ability to recruit immune cells into the treated tumor tissue, resulting in impaired apoptosis and improved cancer cell survival [30].